Navigation Links
Octapharma Announces octagam® 5% Again Available for U.S. Purchase
Date:11/30/2011

HOBOKEN, N.J., Nov. 30, 2011 /PRNewswire/ -- Octapharma USA announced that octagam® [Immune Globulin Intravenous (human) 5% Liquid Preparation] is again available for purchase. The U.S. Food and Drug Administration (FDA) on Nov. 3 approved the U.S. market return of octagam® 5%, a therapy to treat disorders of the immune system.

(Photo: http://photos.prnewswire.com/prnh/20111130/NY14410)

In August 2010, Octapharma initiated a voluntary market withdrawal of octagam® 5% in the U.S. in response to an observed increase in thromboembolic events (TEEs), which occur when a clot or thrombus forms locally in a blood vessel or breaks loose in the blood stream to occlude another vessel. Octapharma has reported that global sales totaled 1.7 million grams of octagam® 5% and octagam® 10%,  [Immune Globulin Intravenous (Human) Liquid Preparation] in the period January 1 through October 30, 2011, an estimated 60,000 treatments, during which there were no reports of TEEs.

"It is a very exciting time for patients throughout the U.S. as they again have access to octagam® 5%, a therapy that has long been valued by the medical community for patient tolerability," said Octapharma USA President Flemming Nielsen. "We have seen over the last year that there are industry-wide concerns over TEEs connected with multiple immune globulin products that remained on the market while we have implemented enhanced safety measures for octagam® 5%. Industry-wide, immune globulin products can lead to TEEs in approximately 1 individual or less for every 10,000 treatments. But our 10-month analysis of octagam® in nearly 60,000 treatments internationally showed that octagam® outperformed this industry benchmark with no reported TEEs."

Octapharma's estimate of 60,000 octagam® 5% and octagam® 10% patient treatments is based on reported global sales of 1.7 million grams, not on actual recorded patient treatment sessions. The number of treatments is based on average patient utilization per treatment. The data has not been submitted to the FDA for evaluation.

The FDA approval to return octagam® 5% to the U.S. market was based on changes Octapharma has made in the manufacturing process and the company's decision to implement a quality control test on every batch of product that is released to the marketplace for the absence of thrombogenic potential. Additionally, Octapharma will implement post-marketing studies to ensure product safety.

Earlier this year, multiple international regulatory agencies authorized the return of octagam® 5% and octagam® 10% in important worldwide markets. The product is presently approved for distribution in the U.S., Austria, Belgium, Bulgaria, Bosnia, Cyprus, Germany, Denmark, Estonia, Spain, Finland, France, Hungary, Iceland, Italy, Lithuania, Luxembourg, Latvia, Malta, Netherlands, Norway, Poland, Portugal, Romania, Serbia, Sweden, Slovenia, Slovakia and the United Kingdom. octagam® 10% is not approved for marketing in the U.S.

For a list of preferred U.S. distributors for octagam® 5%, please visit www.octapharma.us.

About octagam® 5%

Immune Globulin Intravenous (Human), octagam® 5% liquid, is a solvent/detergent (S/D)-treated, sterile preparation of highly purified immunoglobulin G (IgG) derived from large pools of human plasma. octagam® 5% liquid is a solution for infusion which must be administered intravenously.

octagam® is an immune globulin intravenous (human) 5% liquid indicated for treatment of primary humoral immunodeficiency (PI), such as congenital agammaglobulinemia, common variable immunodeficiency, X-linked agammaglobulinemia, Wiskott-Aldrich syndrome and severe combined immunodeficiencies.

About the Octapharma Group

Headquartered in Lachen, Switzerland, Octapharma AG is one of the largest human protein products manufacturers in the world and has been committed to patient care and medical innovation for over 28 years. Octapharma's core business is the development, production and sale of high quality human protein therapies from both human plasma and human cell-lines, including immune globulin intravenous (IGIV). In the U.S., Octapharma's IGIV product, octagam® (immune globulin intravenous [human] 5%), is used to treat primary immune deficiencies, and Octapharma's Albumin (human)® is indicated for the restoration and maintenance of circulating blood volume. Octapharma's wilate® (Von Willebrand Factor/Coagulation Factor VIII Complex [human]) received orphan drug exclusivity from the U.S. Food and Drug Administration (FDA) for the treatment of certain types of Von Willebrand Disease (VWD). Octapharma employs over 4,000 people and has biopharmaceutical experience in 80 countries worldwide, including the United States, where Octapharma USA is located in Hoboken, N.J.  Octapharma operates two state-of-the-art production sites licensed by the FDA, providing a high level of production flexibility. For more information, please visit www.octapharma.com or www.wilateusa.com.

Forward-looking statements

This news release contains forward-looking statements, which include known and unknown risks, uncertainties and other factors not under the company's control. The company assumes no liability whatsoever to update these forward-looking statements or to conform them to future events or developments. These factors include results of current or pending research and development activities and actions by the FDA or other regulatory authorities.


'/>"/>
SOURCE Octapharma USA
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Plasma Products Safe Despite Swine Influenza Outbreak, Assures International Biopharmaceutical Company Octapharma
2. Octapharma Accepting Applications for Research Grants on Immunotherapy, Coagulation Disorders and Critical Care
3. Octapharma Targeting the Major Risk of Hemophilia Treatment - FVIII Antibodies
4. Octapharma USA Announces FDA Approval of wilate(R) - the First Replacement Therapy Developed Specifically for von Willebrand Disease
5. Octapharma Group and Fresenius Kabi Enter Into an Exclusive License, Development and Supply Agreement for a HESylated Recombinant Protein
6. Octapharma Receives Orphan Drug Exclusivity Approval for wilate(R) - A Replacement Therapy Developed Specifically for von Willebrand Disease
7. Octapharma USA Announces Availability and Distributors for wilate®, the First Replacement Therapy Developed Specifically for von Willebrand Disease
8. FDA Confirms Orphan Drug Exclusivity Approval for wilate®, Octapharma USAs New Therapy for Common Inherited Bleeding Disorder
9. Octapharma USA Launches Web Resource for von Willebrand Disease Healthcare Professionals and Patients
10. Octapharma Accepting Applications for Research Grants Focused on Human Protein Therapies
11. Octapharma Clinical Trial Begins in the U.S. and Germany Treating Hemophilia A Patients with First Recombinant Factor VIII Derived from a Human Cell-Line
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/8/2016)... VIEW, Calif. , Dec. 8, 2016 IRIDEX ... intends to offer newly issued shares of common stock, $0.01 ... pursuant to an underwritten public offering.  The final terms of ... the time of pricing, and there can be no assurance ... IRIDEX expects to use the net proceeds it ...
(Date:12/8/2016)... global biosurgery market is expected to grow at a ... to 2021. The market is poised to reach USD ... 2016. The market is primarily driven by rising number ... spinal problems, increasing clearance of biosurgery products by regulatory ... In this report, the biosurgery market is ...
(Date:12/8/2016)... Pharmacy, Inc. (NYSE: DPLO) has been recognized by the Detroit ... Standard. To learn more about Diplomat,s career opportunities, visit ... ... ... LLC, a research firm specializing in organizational health and workplace improvement. ...
Breaking Medicine Technology:
(Date:12/9/2016)... ... December 09, 2016 , ... The ... Hotel in New York, NY, on December 3rd, to benefit Holy Name Medical ... the annual event, which raised over $1 million - the largest event in ...
(Date:12/8/2016)... ... December 08, 2016 , ... The ... beginning January 1, 2017. The name change aligns the entire company with ... improving health care quality. , “We are very proud of the achievements associated ...
(Date:12/8/2016)... ... December 08, 2016 , ... ZyDoc , ... Processing–Enabled and Conventional Data Capture Methods for Input to Electronic Health Records: A ... Results of the comparative usability study demonstrate that a dictation-based method (“NLP Entry”) ...
(Date:12/8/2016)... ... ... the increasing demand for dental implants, the National Association of Dental Laboratories ( NADL ... about the safety issues related to dental restorations. According to the American Academy of ... reach $6.4 billion in 2018 with more than 30 million Americans missing all their ...
(Date:12/8/2016)... ... December 08, 2016 , ... Launching of ... Unified Instance Manager architecture, meeting the needs of multichannel growth and doubling ... unattended auto-dialing system without agents, Presence Robodialer, provides greater operational capacity, administrative ...
Breaking Medicine News(10 mins):